Antibodies News and Research

RSS

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.

24 Jun 2021

Could polio vaccines induce cross-reactive antibodies that target SARS-CoV-2?

A new preprint released on the medRxiv* server explores a link between immunity to SARS-CoV-2, the earlier SARS-CoV, and childhood poliovirus vaccination. Almost 90% of the world’s people have received this vaccine, but antibodies elicited by it reduce over time and are almost absent at the end of adolescence.

24 Jun 2021

New tablet-sized device can profile multiple COVID-19 antibodies and biomarkers simultaneously

Biomedical engineers at Duke University in the USA have developed a device that detects coronavirus disease (COVID-19) antibodies as well as biomarkers that distinguish between antibodies produced in response to SARS-CoV-2 and four other coronaviruses with complete accuracy.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

A new communication concept to detect virus-laden particles

How long do virus-laden particles persist in an elevator after a person infected with COVID-19 leaves? And is there a way to detect those particles? A group of electrical engineers and computer scientists at KAUST set out to answer these questions using mathematical fluid dynamics equations.

24 Jun 2021

Special type of stem cell can reduce the amount of HIV virus

In a groundbreaking study, a team of UC Davis researchers has discovered a special type of stem cell that can reduce the amount of the virus causing AIDS, boosting the body's antiviral immunity and repairing and restoring the gut's lymphoid follicles damaged by the simian immunodeficiency virus (SIV), the equivalent of the human immunodeficiency virus (HIV) in non-human primates.

24 Jun 2021

COVID-19 prevalence in the U.S. has far exceeded the known number of cases

In a new study, National Institutes of Health researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.

24 Jun 2021

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

23 Jun 2021

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

Researchers in India have conducted a study showing that the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – was lower among people living with HIV and AIDS than among the general population.

23 Jun 2021

NIH begins study to evaluate how pregnant, postpartum people react to COVID-19 vaccines

A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum people.

23 Jun 2021

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three members of the University of Colorado Cancer Center and a longstanding supporter of the campus are part of a group of more than 200 researchers nationwide who were recognized in April with the Team Science Award from the American Association for Cancer Research.

23 Jun 2021

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Researchers have suggested that repeated vaccination against SARS-CoV-2 may enable previously uninfected individuals to cope with viral variants.

23 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

A study on hospitalized COVID-19 patients who received plasma therapy

A new study has been published which focuses on the evaluation of the outcomes of infected COVID-19 patients who were treated with CCP therapy.

23 Jun 2021

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Researchers found antibody levels in mRNA vaccinated individuals varied with age, gender, and previous coronavirus disease (COVID-19) infection.

23 Jun 2021

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

New research published in the journal Viruses suggests recovering from a coronavirus disease 2019 (COVID-19) infection provides immunity against the B.1.1.7 (or UK) variant. The time when the previous infection took place and the variant involved in prior infection influenced cross-neutralization.

23 Jun 2021

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

As many as 16.8 million Americans had undiagnosed SARS-CoV-2 infections - 5 times the rate of diagnosed infections - by the end of July of 2020, according to an analysis of antibodies from more than 8,000 previously undiagnosed adults collected during the pandemic's first wave.

23 Jun 2021

Antibodies News and Research

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

Could polio vaccines induce cross-reactive antibodies that target SARS-CoV-2?

New tablet-sized device can profile multiple COVID-19 antibodies and biomarkers simultaneously

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A new communication concept to detect virus-laden particles

Special type of stem cell can reduce the amount of HIV virus

COVID-19 prevalence in the U.S. has far exceeded the known number of cases

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

NIH begins study to evaluate how pregnant, postpartum people react to COVID-19 vaccines

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

A study on hospitalized COVID-19 patients who received plasma therapy

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Researchers review the origins of SARS-CoV-2 and present treatment methods

New study enrolls young adults to evaluate SARS-CoV-2 infection

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo